Lyra Therapeutics
LYRA
LYRA
37 hedge funds and large institutions have $138M invested in Lyra Therapeutics in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
19% more funds holding
Funds holding: 31 → 37 (+6)
0.93% more ownership
Funds ownership: 1.19% → 2.12% (+0.93%)
Holders
37
Holding in Top 10
1
Calls
$1M
Puts
$2K
Top Buyers
| 1 | +$16.5M | |
| 2 | +$14.8M | |
| 3 | +$11.7M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$7.14M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.12M |
Top Sellers
| 1 | -$2.36M | |
| 2 | -$206K | |
| 3 | -$120K | |
| 4 |
Two Sigma Advisers
New York
|
-$56.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$34.7K |